Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy /N. V. Litvyakov, N. V. Cherdyntseva, M. M. Tsyganov [et.al.]

Электронный ресурс
Другой Автор
Cherdyntseva, Nadezhda V.
Tsyganov, Matvey M.
Slonimskaya, Elena M.
Ibragimova, Marina K.
Kazantseva, Polina V.
Kzhyshkowska, Julia G
Choinzonov, Evgeny L.
Источник
Oncotarget 2016 Vol. 7, № 7. P. 7829-7841
Аннотация
Neoadjuvant chemotherapy (NAC) is intensively used for the treatment of primary breast cancer. In our previous studies, we reported that clinical tumor response to NAC is associated with the change of multidrug resistance (MDR) gene expression in tumors after chemotherapy. In this study we performed a combined analysis of MDR gene locus deletions in tumor DNA, MDR gene expression and clinical response to NAC in 73 BC patients. Copy number variations (CNVs) in biopsy specimens were tested using high-density microarray platform CytoScanTM HD Array (Affymetrix, USA). 75%-100% persons having deletions of MDR gene loci demonstrated the down-regulation of MDR gene expression. Expression of MDR genes was 2-8 times lower in patients with deletion than in patients having no deletion only in post-NAC tumors samples but not in tumor tissue before chemotherapy. All patients with deletions of ABCB1 ABCB 3 ABCC5 gene loci--7q21.1, 6p21.32, 3q27 correspondingly, and most patients having deletions in ABCC1 (16p13.1), ABCC2 (10q24), ABCG1 (21q22.3), ABCG2 (4q22.1), responded favorably to NAC. The analysis of all CNVs, including both amplification and deletion showed that the frequency of 13q14.2 deletion was 85% among patients bearing tumor with the deletion at least in one MDR gene locus versus 9% in patients with no deletions. Differences in the frequency of 13q14.2 deletions between the two groups were statistically significant (p = 2.03 × 10(-11), Fisher test, Bonferroni-adjusted p = 1.73 × 10(-8)). In conclusion, our study for the first time demonstrates that deletion MDR gene loci can be used as predictive marker for tumor response to NAC.
Всего оценка: 0
Нет записей для отображения.
 
 
 
03212nab a2200373 c 4500
001
 
 
vtls000553236
003
 
 
RU-ToGU
005
 
 
20181202154300.0
007
 
 
cr |
008
 
 
181202|2016    xxu     s         a eng d
024
7
$a 10.18632/oncotarget.6953 $2 doi
035
$a to000553236
039
9
$a 201812021543 $b staff $c 201612150902 $d cat202 $c 201612131556 $d VLOAD $y 201612131541 $z VLOAD
040
$a RU-ToGU $b rus $c RU-ToGU
245
1
0
$a Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy $c N. V. Litvyakov, N. V. Cherdyntseva, M. M. Tsyganov [et.al.]
504
$a Библиогр.: 46 назв.
520
3
$a Neoadjuvant chemotherapy (NAC) is intensively used for the treatment of primary breast cancer. In our previous studies, we reported that clinical tumor response to NAC is associated with the change of multidrug resistance (MDR) gene expression in tumors after chemotherapy. In this study we performed a combined analysis of MDR gene locus deletions in tumor DNA, MDR gene expression and clinical response to NAC in 73 BC patients. Copy number variations (CNVs) in biopsy specimens were tested using high-density microarray platform CytoScanTM HD Array (Affymetrix, USA). 75%-100% persons having deletions of MDR gene loci demonstrated the down-regulation of MDR gene expression. Expression of MDR genes was 2-8 times lower in patients with deletion than in patients having no deletion only in post-NAC tumors samples but not in tumor tissue before chemotherapy. All patients with deletions of ABCB1 ABCB 3 ABCC5 gene loci--7q21.1, 6p21.32, 3q27 correspondingly, and most patients having deletions in ABCC1 (16p13.1), ABCC2 (10q24), ABCG1 (21q22.3), ABCG2 (4q22.1), responded favorably to NAC. The analysis of all CNVs, including both amplification and deletion showed that the frequency of 13q14.2 deletion was 85% among patients bearing tumor with the deletion at least in one MDR gene locus versus 9% in patients with no deletions. Differences in the frequency of 13q14.2 deletions between the two groups were statistically significant (p = 2.03 × 10(-11), Fisher test, Bonferroni-adjusted p = 1.73 × 10(-8)). In conclusion, our study for the first time demonstrates that deletion MDR gene loci can be used as predictive marker for tumor response to NAC.
653
$a неоадъювантная химиотерапия
653
$a гены
653
$a рак молочной железы
655
4
$a статьи в журналах
700
1
$a Cherdyntseva, Nadezhda V.
700
1
$a Tsyganov, Matvey M.
700
1
$a Slonimskaya, Elena M.
700
1
$a Ibragimova, Marina K.
700
1
$a Kazantseva, Polina V.
700
1
$a Kzhyshkowska, Julia G
700
1
$a Choinzonov, Evgeny L.
773
0
$t Oncotarget $d 2016 $g Vol. 7, № 7. P. 7829-7841 $x 1949-2553
852
4
$a RU-ToGU
856
7
$u http://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000553236
908
$a статья
999
$a VIRTUA
999
$a VTLSSORT0010*0030*0050*0070*0080*0240*0350*0390*0400*2450*5040*5200*6530*6531*6532*6550*7000*7001*7002*7003*7004*7005*7006*7730*8520*8560*9080*9992
Нет комментариев.
Предмет
статьи в журналах
Резюме
Neoadjuvant chemotherapy (NAC) is intensively used for the treatment of primary breast cancer. In our previous studies, we reported that clinical tumor response to NAC is associated with the change of multidrug resistance (MDR) gene expression in tumors after chemotherapy. In this study we performed a combined analysis of MDR gene locus deletions in tumor DNA, MDR gene expression and clinical response to NAC in 73 BC patients. Copy number variations (CNVs) in biopsy specimens were tested using high-density microarray platform CytoScanTM HD Array (Affymetrix, USA). 75%-100% persons having deletions of MDR gene loci demonstrated the down-regulation of MDR gene expression. Expression of MDR genes was 2-8 times lower in patients with deletion than in patients having no deletion only in post-NAC tumors samples but not in tumor tissue before chemotherapy. All patients with deletions of ABCB1 ABCB 3 ABCC5 gene loci--7q21.1, 6p21.32, 3q27 correspondingly, and most patients having deletions in ABCC1 (16p13.1), ABCC2 (10q24), ABCG1 (21q22.3), ABCG2 (4q22.1), responded favorably to NAC. The analysis of all CNVs, including both amplification and deletion showed that the frequency of 13q14.2 deletion was 85% among patients bearing tumor with the deletion at least in one MDR gene locus versus 9% in patients with no deletions. Differences in the frequency of 13q14.2 deletions between the two groups were statistically significant (p = 2.03 × 10(-11), Fisher test, Bonferroni-adjusted p = 1.73 × 10(-8)). In conclusion, our study for the first time demonstrates that deletion MDR gene loci can be used as predictive marker for tumor response to NAC.